

PETNET Solutions Announces Domestic and International Expansion at SNM 2010

54 production facilities serve a global market: U.S., U.K., Korea, Spain, Australia; more on the way

Salt Lake City, Utah, June 6, 2010 – PETNET Solutions (booth #1235), a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., announces the expansion of its PET radiopharmaceutical network internationally and in the United States. Already a leader in the production and delivery of PET imaging biomarkers in the U.S., the United Kingdom and South Korea, PETNET added three production and distribution facilities worldwide. PETNET has expanded to Albuquerque, N.M.; Madrid, Spain; and Sydney, Australia. Further international expansion will build a PETNET presence in France, Singapore and India – completing the first phase of international expansion and contributing to a truly global footprint.

As the utilization of PET/CT imaging increases, PETNET Solutions addresses the need to manufacture and deliver PET imaging agents in all of these countries, as well as continue growth in the U.S. Siemens and PETNET Solutions partnered with the University of New Mexico Cancer Center on its new, state-of-the-art-cancer facility, whose dedication ceremony is scheduled for June 11, 2010. Operation is also underway at PETNET Australia, an affiliation with the Australian Nuclear Science and Technology Organization, as well as in Madrid, Spain.

“The University of New Mexico Cancer Center, working together with Siemens, is important, as we think about serving the metropolitan area of Albuquerque,” says Britta Fuenfstueck, chief executive officer, Molecular Imaging, Siemens Healthcare. “It’s also very promising to see the international expansion of PETNET Solutions, where we are bringing PETNET manufacture and delivery capabilities for various tracers to places, such as Australia, Spain, Singapore, France and India.”

PETNET Solutions operates the largest PET radiopharmaceutical network with 54 production and distribution centers worldwide that manufacture and distribute PET biomarkers to hospitals, clinics, and research facilities for PET imaging. In addition, PETNET Solutions is committed to advancing

molecular imaging through the integrated discovery and development program of Siemens Molecular Imaging Biomarker Research, as well as supplying clinical trials of investigational PET imaging agents developed by third parties. Recently, PETNET has expanded production and availability of Sodium Fluoride (^{18}F -NaF) and helped offset shortages in the supply of molybdenum and $^{99\text{m}}\text{Tc}$ -labeled radiopharmaceuticals through an ^{18}F -NaF Sodium Fluoride trial program

The **Siemens Healthcare Sector** is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2009 (to September 30), the Sector posted revenue of 11.9 billion euros and profit of around 1.5 billion euros. For further information please visit: www.siemens.com/healthcare.